Premium
Increased Biomarkers of Metabolic Syndrome in Total Joint Arthoplasty Patients
Author(s) -
Banos Andrew,
Hopkinson William,
Rees Harold,
Syed Daneyal,
Abro Schuharazad,
Hoppensteadt Debra,
Iqbal Omer,
Saluk Jennifer,
Fareed Jawed
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.766.8
Subject(s) - medicine , leptin , resistin , ferritin , arthroplasty , insulin , biomarker , gastroenterology , insulin resistance , surgery , adiponectin , obesity , biology , biochemistry
Patients undergoing total hip and total knee arthroplasty (THA/TKA) represent a diverse group with a variety of pre‐existing co‐morbidities including metabolic syndrome (Mes). Recently several biomarkers of Mes have been identified and may be helpful in the risk stratification and management of arthroplasty patients. This study is designed to profile biomarkers of Mes in total joint arthroplasty patients. Citrated plasma samples were collected from 42 patients undergoing THA/TKA pre‐operatively and day 1 post‐operatively (POD1). Control group consisted of 48 healthy, non‐smoking and non‐medicated donors. Both were profiled for Mes biomarkers utilizing biochip array technology which included C‐peptide, ferritin, IL‐6, insulin, resistin, TNFa, IL‐1a, leptin, and PAI‐1. Compared to normal controls, pre‐operative levels of C‐peptide and ferritin did not differ significantly (p>0.05). IL‐6, resistin, insulin, TNFa, IL‐1a, leptin, and PAI‐1 levels were significantly higher in the arthroplasty group (p<0.05 to 0.001). Post operative plasma samples exhibited marked augmentation of the biomarkers of Mes with wider variations. The pre‐existing Mes has been reported to contribute to surgical complications in THA/TKA. The increased levels of leptin, insulin, C‐peptide, along with inflammatory biomarkers underscore the interplay of Mes mediators and inflammatory process. Profiling of Mes biomarkers provides an added tool to risk stratify arthroplasty patients and optimize their clinical management.